Science 19 September 1986: Vol. 233. no. 4770, pp. 1318 - 1321 DOI: 10.1126/science.3489291

Prev | Table of Contents | Next

Articles

T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective.

A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord (2009)
Clin. Cancer Res. 15, 6503-6510
 |  Abstract »  |  Full Text »  |  PDF »

Immunotherapy of distant metastatic disease.

D. Schadendorf, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M. M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, et al. (2009)
Ann. Onc. 20, vi41-vi50
 |  Abstract »  |  Full Text »  |  PDF »

Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity.

Y.-C. Lin, L.-Y. Chang, C.-T. Huang, H.-M. Peng, A. Dutta, T.-C. Chen, C.-T. Yeh, and C.-Y. Lin (2009)
J. Immunol. 182, 6095-6104
 |  Abstract »  |  Full Text »  |  PDF »

Large-Scale Production and Characterization of Novel CD4+ Cytotoxic T Cells with Broad Tumor Specificity for Immunotherapy.

C. Jursik, M. Prchal, R. Grillari-Voglauer, K. Drbal, E. Fuertbauer, H. Jungfer, W. H. Albert, E. Steinhuber, T. Hemetsberger, J. Grillari, et al. (2009)
Mol. Cancer Res. 7, 339-353
 |  Abstract »  |  Full Text »  |  PDF »

Serotonin Regulates Macrophage-Mediated Angiogenesis in a Mouse Model of Colon Cancer Allografts.

A. Nocito, F. Dahm, W. Jochum, J. H. Jang, P. Georgiev, M. Bader, R. Graf, and P.-A. Clavien (2008)
Cancer Res. 68, 5152-5158
 |  Abstract »  |  Full Text »  |  PDF »

Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}.

S. Wei, A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang (2008)
Cancer Res. 68, 5432-5438
 |  Abstract »  |  Full Text »  |  PDF »

Interleukin 21 Enhances Antibody-Mediated Tumor Rejection.

M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw (2008)
Cancer Res. 68, 3019-3025
 |  Abstract »  |  Full Text »  |  PDF »

Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity.

E. Ko, W. Luo, L. Peng, X. Wang, and S. Ferrone (2007)
Cancer Res. 67, 7875-7884
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.

L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz (2007)
Blood 109, 4865-4876
 |  Abstract »  |  Full Text »  |  PDF »

CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma.

B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby (2007)
Clin. Cancer Res. 13, 388-397
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions.

G. Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, A. J. Treves, R. S. Blumberg, R. Loewenthal, et al. (2006)
J. Immunol. 177, 6062-6071
 |  Abstract »  |  Full Text »  |  PDF »

Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes.

L. A. Johnson, B. Heemskerk, D. J. Powell Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg (2006)
J. Immunol. 177, 6548-6559
 |  Abstract »  |  Full Text »  |  PDF »

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer..

M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. (2006)
Clin. Cancer Res. 12, 6106-6115
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.

R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. (2006)
Science 314, 126-129
 |  Abstract »  |  Full Text »  |  PDF »

Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors.

H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern (2006)
J. Immunol. 177, 4288-4298
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. (2006)
Blood 108, 1797-1808
 |  Abstract »  |  Full Text »  |  PDF »

Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin..

J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh (2006)
Cancer Res. 66, 4913-4921
 |  Abstract »  |  Full Text »  |  PDF »

Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice.

M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito (2005)
Cancer Res. 65, 10032-10040
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.

M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. (2005)
Blood 106, 2995-3003
 |  Abstract »  |  Full Text »  |  PDF »

Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing.

A. M. Kleinfeld and C. Okada (2005)
J. Lipid Res. 46, 1983-1990
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma.

M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. (2005)
J. Clin. Oncol. 23, 2346-2357
 |  Abstract »  |  Full Text »  |  PDF »

Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors.

K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello (2005)
Cancer Res. 65, 2026-2034
 |  Abstract »  |  Full Text »  |  PDF »

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.

S. A. Rosenberg and M. E. Dudley (2004)
PNAS 101, 14639-14645
 |  Abstract »  |  Full Text »  |  PDF »

Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo.

Y. Lou, G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu (2004)
Cancer Res. 64, 6783-6790
 |  Abstract »  |  Full Text »  |  PDF »

Novel OK-432-conjugated Tumor Vaccines Induce Tumor-specific Immunity against Murine Tongue Cancer.

X. Li, H. Bukawa, M. Hirota, Y. Tsuyuki, S. Omura, and K. Fujita (2003)
Journal of Dental Research 82, 636-640
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells.

B. Blanco, P. Holliger, R. G. Vile, and L. Alvarez-Vallina (2003)
J. Immunol. 171, 1070-1077
 |  Abstract »  |  Full Text »  |  PDF »

Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability.

A. L. Epstein, M. M. Mizokami, J. Li, P. Hu, and L. A. Khawli (2003)
J Natl Cancer Inst 95, 741-749
 |  Abstract »  |  Full Text »  |  PDF »

Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer.

A. E. Chang, Q. Li, G. Jiang, D. M. Sayre, T. M. Braun, and B. G. Redman (2003)
J. Clin. Oncol. 21, 884-890
 |  Abstract »  |  Full Text »  |  PDF »

TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells.

C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox (2003)
J. Immunol. 170, 2004-2013
 |  Abstract »  |  Full Text »  |  PDF »

Dendritic Cell-Based Vaccination in Solid Cancer.

A. Stift, J. Friedl, P. Dubsky, T. Bachleitner-Hofmann, G. Schueller, T. Zontsich, T. Benkoe, K. Radelbauer, C. Brostjan, R. Jakesz, et al. (2003)
J. Clin. Oncol. 21, 135-142
 |  Abstract »  |  Full Text »  |  PDF »

Interleukin 15 Promotes Antigen-independent in Vitro Expansion and Long-Term Survival of Antitumor Cytotoxic T Lymphocytes.

J. Lu, R. L. Giuntoli II, R. Omiya, H. Kobayashi, R. Kennedy, and E. Celis (2002)
Clin. Cancer Res. 8, 3877-3884
 |  Abstract »  |  Full Text »  |  PDF »

Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation.

N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy (2002)
J. Immunol. 169, 5780-5786
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. (2002)
Science 298, 850-854
 |  Abstract »  |  Full Text »  |  PDF »

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy (2002)
Blood 100, 3155-3163
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion.

L.-X. Wang, B.-G. Chen, and G. E. Plautz (2002)
J. Immunol. 169, 3314-3320
 |  Abstract »  |  Full Text »  |  PDF »

Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity.

S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska (2002)
J. Immunol. 169, 531-539
 |  Abstract »  |  Full Text »  |  PDF »

Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression.

H. Huang, F. Li, J. R. Gordon, and J. Xiang (2002)
Cancer Res. 62, 2043-2051
 |  Abstract »  |  Full Text »  |  PDF »

Campbell De Morgan's 'Observations on cancer', and their relevance today.

J. M Grange, J. L Stanford, and C. A Stanford (2002)
J R Soc Med 95, 296-299
 |  Full Text »  |  PDF »

Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity.

K. Liu and S. A. Rosenberg (2001)
J. Immunol. 167, 6356-6365
 |  Abstract »  |  Full Text »  |  PDF »

Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity.

R. A. Kemp and F. Ronchese (2001)
J. Immunol. 167, 6497-6502
 |  Abstract »  |  Full Text »  |  PDF »

Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor.

J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu (2001)
J. Immunol. 167, 6669-6677
 |  Abstract »  |  Full Text »  |  PDF »

Effects of Social Housing Condition on Chemotherapeutic Efficacy in a Shionogi Carcinoma (SC115) Mouse Tumor Model: Influences of Temporal Factors, Tumor Size, and Tumor Growth Rate.

L. R. Kerr, R. Hundal, W. A. Silva, J. T. Emerman, and J. Weinberg (2001)
Psychosom Med 63, 973-984
 |  Abstract »  |  Full Text »  |  PDF »

CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome.

S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, and T. E. Witzig (2001)
J. Clin. Oncol. 19, 720-726
 |  Abstract »  |  Full Text »  |  PDF »

Locoregional Cellular Immunotherapy for Patients with Advanced Esophageal Cancer.

U. Toh, H. Yamana, S. Sueyoshi, T. Tanaka, F. Niiya, K. Katagiri, H. Fujita, K. Shirozou, and K. Itoh (2000)
Clin. Cancer Res. 6, 4663-4673
 |  Abstract »  |  Full Text »

Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression.

L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen (2000)
J. Immunol. 165, 5738-5749
 |  Abstract »  |  Full Text »  |  PDF »

Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy.

H.-M. Hu, H. Winter, W. J. Urba, and B. A. Fox (2000)
J. Immunol. 165, 4246-4253
 |  Abstract »  |  Full Text »  |  PDF »

Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study.

W. C. To, B. G. Wood, J. C. Krauss, M. Strome, R. M. Esclamado, P. Lavertu, D. Dasko, J. A. Kim, G. E. Plautz, B. E. Leff, et al. (2000)
Arch Otolaryngol Head Neck Surg 126, 1225-1231
 |  Abstract »  |  Full Text »  |  PDF »

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity.

J. Shimizu, S. Yamazaki, and S. Sakaguchi (1999)
J. Immunol. 163, 5211-5218
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Infiltration by Adoptively Transferred T Cells Is Independent of Immunologic Specificity but Requires Down-Regulation of L-Selectin Expression.

J. Kjaergaard and S. Shu (1999)
J. Immunol. 163, 751-759
 |  Abstract »  |  Full Text »  |  PDF »

Cytotoxic T-Lymphocyte Epitope Immunodominance in the Control of Choroid Plexus Tumors in Simian Virus 40 Large T Antigen Transgenic Mice.

T. D. Schell, L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia (1999)
J. Virol. 73, 5981-5993
 |  Abstract »  |  Full Text »  |  PDF »

An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer.

D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Cerottini, and P. Romero (1999)
Cancer Res. 59, 2167-2173
 |  Abstract »  |  Full Text »  |  PDF »

Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination.

N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole (1999)
Clin. Cancer Res. 5, 1173-1182
 |  Abstract »  |  Full Text »  |  PDF »

Successful Adoptive Immunotherapy of Murine Poorly Immunogenic Tumor with Specific Effector Cells Generated from Gene-Modified Tumor-Primed Lymph Node Cells.

H. Tanaka, H. Yoshizawa, Y. Yamaguchi, K. Ito, H. Kagamu, E. Suzuki, F. Gejyo, H. Hamada, and M. Arakawa (1999)
J. Immunol. 162, 3574-3582
 |  Abstract »  |  Full Text »  |  PDF »

Immune surveillance against a solid tumor fails because of immunological ignorance.

A. F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel (1999)
PNAS 96, 2233-2238
 |  Abstract »  |  Full Text »  |  PDF »

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.

K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule (1999)
PNAS 96, 2268-2273
 |  Abstract »  |  Full Text »  |  PDF »

Stimulation of Tumors to Synthesize Tumor Necrosis Factor-{{alpha}} in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid: A Novel Approach to Cancer Therapy.

W. R. Joseph, Z. Cao, K. G. Mountjoy, E. S. Marshall, B. C. Baguley, and L.-M. Ching (1999)
Cancer Res. 59, 633-638
 |  Abstract »  |  Full Text »  |  PDF »

Expanded Tumor-reactive CD4+ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation.

Q. Li, S. A. Furman, C. R. Bradford, and A. E. Chang (1999)
Clin. Cancer Res. 5, 461-469
 |  Abstract »  |  Full Text »  |  PDF »

Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue.

T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura (1999)
J. Immunol. 162, 1749-1755
 |  Abstract »  |  Full Text »  |  PDF »

Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3.

G. Strau{beta}, B. Guckel, D. Wallwiener, and G. Moldenhauer (1999)
Clin. Cancer Res. 5, 171-180
 |  Abstract »  |  Full Text »  |  PDF »

Tumor-Infiltrating Lymphocytes Exhibiting High Ex Vivo Cytolytic Activity Fail to Prevent Murine Melanoma Tumor Growth In Vivo.

A. Prevost-Blondel, C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher (1998)
J. Immunol. 161, 2187-2194
 |  Abstract »  |  Full Text »  |  PDF »

Activation Requirements, Lytic Mechanism, and Development of a Novel Anti-CD8-Resistant CTL Population.

S. A. McCarthy, M. S. Mainwaring, D. S. Dougall, and E. S. Lamouse-Smith (1998)
J. Immunol. 160, 2715-2724
 |  Abstract »  |  Full Text »  |  PDF »

Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes.

M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein (1998)
J. Immunol. 160, 334-344
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Immunology.

S. Shu, G. E. Plautz, J. C. Krauss, and A. E. Chang (1997)
JAMA 278, 1972-1981
 |  Abstract »  |  PDF »

Evidence for the Participation of Interleukin-2 (IL-2) and IL-4 in the Regulation of Autonomous Growth and Tumorigenesis of Transformed Cells of Lymphoid Origin.

M. R. Hassuneh, P. S. Nagarkatti, and M. Nagarkatti (1997)
Blood 89, 610-620
 |  Abstract »  |  Full Text »  |  PDF »

Topical Review: Gene Therapy for Neurologic Disease: Benchtop Discoveries to Bedside Applications. 1. The Bench.

B. L. Maria, C. D. Medina, K. B.N. Hoang, and M. I. Phillips (1997)
J Child Neurol 12, 1-12
 |  Abstract »  |  PDF »

Sensitization of Nude Mice Using Direct Liposome Transfer of Tumor Cell Antigens.

T. Ariyasu, O. Ike, S. Hitomi, H. Wada, Y. Okumura, and J. Sunamoto (1996)
Journal of Bioactive and Compatible Polymers 11, 191-202
 |  Abstract »

Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid.

D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu (1995)
Reproductive Sciences 2, 762-771
 |  Abstract »  |  PDF »

Treatment of Metastatic Melanoma and Renal Cell Carcinoma With Interleukin-2.

L. A. Manson (1994)
JAMA 272, 1327
 |  Abstract »  |  PDF »

Immunobiologic Effects of Cytokine Gene Transfer of the B16-BL6 Melanoma.

S. E. Strome, J. C. Krauss, M. J. Cameron, K. Forslund, S. Shu, and A. E. Chang (1993)
Arch Otolaryngol Head Neck Surg 119, 1289-1295
 |  Abstract »  |  PDF »

Adoptive Cellular Therapy of Malignancy.

A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu (1993)
Arch Surg 128, 1281-1290
 |  Abstract »  |  PDF »

Gene Therapy for Cancer.

S. A. Rosenberg (1992)
JAMA 268, 2416-2419
 |  Abstract »  |  PDF »

Treatment of Human Melanoma Hepatic Metastases in Nude Mice With Human Cytotoxic T Lymphocytes.

N. J. Crowley, C. E. Vervaert, and H. F. Seigler (1991)
Arch Surg 126, 433-437
 |  Abstract »  |  PDF »

Enhanced Antitumor Reactivity of TumorSensitized T Cells by Interferon Alfa.

D. L. V. Woude, P. D. Wagner, S. Shu, and A. E. Chang (1991)
Arch Surg 126, 307-313
 |  Abstract »  |  PDF »

Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human Cancers.

C. M. Balch, L. B. Riley, Y. J. Bae, M. A. Salmeron, C. D. Platsoucas, A. von Eschenbach, and K. Itoh (1990)
Arch Surg 125, 200-205
 |  Abstract »  |  PDF »

Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal Metastases.

A. Calabro, S. E. Singletary, and C. M. Balch (1989)
Arch Surg 124, 1051-1055
 |  Abstract »  |  PDF »

Production of Lymphokine-Activated Lymphocytes: Lysis of Human Head and Neck Squamous Cell Carcinoma Cell Lines.

D. M. Alessi, R. W. Hutcherson, and R. A. Mickel (1989)
Arch Otolaryngol Head Neck Surg 115, 725-730
 |  Abstract »  |  PDF »

Hepatectomy Prolongs Survival of Mice With Induced Liver Metastases.

M. H. Castillo, R. J. Doerr, N. Paolini Jr, S. Cohen, and M. Goldrosen (1989)
Arch Surg 124, 167-169
 |  Abstract »  |  PDF »

Natural Killer Activity of Lymphocytes Infiltrating Human Lung Cancers Following Preoperative Systemic Recombinant Interleukin 2.

T. M. Anderson, Y. Ibayashi, Y. Tokuda, S. Colquhoun, C. Holmes, and S. H. Golub (1987)
Arch Surg 122, 1446-1450
 |  Abstract »  |  PDF »

To Advertise   |   Find Products